HajarizadehB,GrebelyJ,DoreGJ, 2013.Epidemiology and natural history of HCV infection,Nature Reviews Gastroenterology and Hepatology 10 553 -8
ZeremskiM,DimovaRB,PillardyJ,de JongYP,JacobsonIM,TalalAH, 2016.Fibrosis progression in patients with chronic hepatitis C virus infection,J Infect Dis 214 1164 -70
VescovoT,RefoloG,VitaglianoG,FimiaGM,PiacentiniM., 2016.Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma,Clinical Microbiology and Infection 22 853 -61
HepatitisC,Infection Dammacco F , Sansonno,D, 2013.Therapy for hepatitis C virus-related cryoglobulinemic vasculitis,N Eng J of Med 369 1035 -45
CacoubP,SaadounD,LimalN,SeneD,LidoveO,PietteJC, 2005.PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis,Arthritis & Rheumatism 52 911 -5
MazzaroC,MontiG,SaccardoF,ZignegoAL,FerriC,De Vita S, .Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study, -
2011.,Clinical and Experimental Rheumatology 2 933 -6
ZhangJ,NguyenD,HuKQ, 2016.Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies,N Am J of Med Sci 9 47 -55
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,N Eng J Med 368 34 -44
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Eng J Med 368 1878 -87
PolS,SulkowskiM,HassaneinT,GaneE,LiyunN,HoH, 2014.Successful retreatment with Sofosbuvir of HCV Genotype-1 infected patients who failed prior theraphy with PEG-Interferon+ Ribavarin plus 1 or 2 additional DAA's,J Hepatology 60 S23 -5
MangiaA,PiazzollaV, 2014.Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies,Digestive and Liver Disease 46 S179 -85
AhmadB,AliS,AliI,MahmoodN,BashirS,NawazS., 2013.Conventional interferon therapy response among chronic HCV patients in Khyber Pakhtunkhwa,Journal of Infectious Diseases and Therapy 1 -3
AliS,AhmadB,AliI,MahmoodN,AnwarN,SaeediI, 2016.Virological response to conventional interferon therapy combined with ribavirin against various HCV genotypes in Khyber Pakhtunkhwa, Pakistan,Asian Pacific Journal of Cancer Prevention 17 2407 -10
GragnaniL,VisentiniM,FognaniE,UrraroT,De SantisA,PetracciaL, 2016.Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia,Hepatology 64 1473 -82
DammaccoF,TucciFA,LaulettaG,GattiP,De ReV,ConteducaV, 2010.Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study,Blood 2009 -14
SaadounD,RigonMR,PolS,ThibaultV,BlancF,PialouxG,AliA,AbbasiAS,ShaikhJI, 2017.Demographic features of HCV in Pakistani population,J Med Sci 25 252 -7
HaiderI,HumayunM., 2017.The global burden of HCV,J Med Sci 25 281 -2